Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 12/20 | 1.00 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.63 |
| ▸ | DDT | P30046 | 1/20 | 0.62 |
| ▸ | AR | P10275 | 1/20 | 0.60 |
| ▸ | CA12 | O43570 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21792297 | 0.85 | NOTUM (0.74) | NOTUMGPR119DDTARKCNH2 | |
| SCHEMBL21776821 | 0.83 | NOTUM (0.75) | NOTUMGPR119DDTCA12CA1 | |
| SCHEMBL21792125 | 0.81 | NOTUM (1.00) | NOTUMDDTCA12CA1CA2 | |
| SCHEMBL1790343 | 0.80 | NOTUM (0.66) | NOTUMGPR119DDTRAB9A | |
| SCHEMBL5904691 | 0.80 | NOTUM (0.66) | NOTUMGPR119DDTCA12CA1 | |
| SCHEMBL15677781 | 0.79 | NOTUM (0.64) | NOTUMGPR119DDTRAB9A | |
| SCHEMBL21792139 | 0.76 | NOTUM (1.00) | NOTUM | |
| SCHEMBL26085015 | 0.75 | NOTUM (0.64) | NOTUMCA12CA1CA2CA9 | |
| SCHEMBL23451838 | 0.74 | NOTUM (1.00) | NOTUMARKCNH2 | |
| SCHEMBL21792038 | 0.73 | NOTUM (1.00) | NOTUMCA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11634391-B2 | Compounds which are inhibitors of Notum | UCL BUSINESS LTD (GB) | 2023-04-25 | — | — | US | disclosed |
| EP-3843844-A1 | COMPOUNDS | UCL Business Ltd (GB) | 2021-07-07 | — | — | EP | disclosed |
| US-20210171475-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2021-06-10 | — | — | US | disclosed |
| US-20210171475-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2021-06-10 | — | — | US | disclosed |
| WO-2020043866-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2020-03-05 | — | — | WO | disclosed |
| WO-2020043866-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11634391-B2 | Compounds which are inhibitors of Notum | NOTUM, GOT2, GOT1 | NOTUM 1/4885GPR119 2681/4885DDT 2572/4885 |
| US-20210171475-A1 | COMPOUNDS | GOT2, GOT1, OAT | NOTUM 5/4885GPR119 498/4885DDT 2754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.